Eton Pharmaceuticals, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Eton Pharmaceuticals, Inc. (ETON) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $1.47 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-13
- Eton Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $1.47M, a 29.96% decline year-over-year.
- Eton Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $1.52M, a 26.50% increase year-over-year.
- Eton Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $1.12M, a 43.73% increase year-over-year.
- Eton Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $1.09M, a 51.25% increase year-over-year.
- Eton Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $5.51M, a 74.15% increase from fiscal 2024.
- Eton Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $3.17M, a 0.89% increase from fiscal 2023.
- Eton Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $3.14M, a 25.63% decline from fiscal 2022.
- Eton Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $4.22M, a 24.76% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 24 month |
|---|---|---|---|---|---|
| 2026-06-30 | $1.47M 10-Q · filed 2026-08-13 | $2.99M 10-Q · filed 2026-08-13 | $4.11M derived: sum of 3 quarters · filed 2026-08-13 | $5.20M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | $1.52M 10-Q · filed 2026-05-14 | $2.64M derived: sum of 2 quarters · filed 2026-05-14 | $3.73M derived: sum of 3 quarters · filed 2026-05-14 | $5.83M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | $1.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $2.22M derived: sum of 2 quarters · filed 2026-03-19 | $4.31M derived: sum of 3 quarters · filed 2026-08-13 | $5.51M 10-K · filed 2026-03-19 | |
| 2025-09-30 | $1.09M 10-Q · filed 2025-11-06 | $3.19M derived: sum of 2 quarters · filed 2026-08-13 | $4.39M 10-Q · filed 2025-11-06 | $5.17M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | $2.10M 10-Q · filed 2026-08-13 | $3.30M 10-Q · filed 2026-08-13 | $4.08M derived: sum of 3 quarters · filed 2026-08-13 | $4.80M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | $1.20M 10-Q · filed 2026-05-14 | $1.98M derived: sum of 2 quarters · filed 2026-05-14 | $2.70M derived: sum of 3 quarters · filed 2026-05-14 | $3.54M derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | $782.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $1.50M derived: sum of 2 quarters · filed 2026-03-19 | $2.34M derived: sum of 3 quarters · filed 2026-03-19 | $3.17M 10-K · filed 2026-03-19 | |
| 2024-09-30 | $722.00K 10-Q · filed 2025-11-06 | $1.56M derived: sum of 2 quarters · filed 2025-11-06 | $2.38M 10-Q · filed 2025-11-06 | $3.13M derived: sum of 4 quarters · filed 2026-03-19 | |
| 2024-06-30 | $840.00K 10-Q · filed 2025-08-07 | $1.66M 10-Q · filed 2025-08-07 | $2.41M derived: sum of 3 quarters · filed 2026-03-19 | $3.14M derived: sum of 4 quarters · filed 2026-03-19 | |
| 2024-03-31 | $821.00K 10-Q · filed 2025-05-13 | $1.57M derived: sum of 2 quarters · filed 2026-03-19 | $2.30M derived: sum of 3 quarters · filed 2026-03-19 | $3.09M derived: sum of 4 quarters · filed 2026-03-19 | |
| 2023-12-31 | $750.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $1.48M derived: sum of 2 quarters · filed 2026-03-19 | $2.27M derived: sum of 3 quarters · filed 2026-03-19 | $3.14M 10-K · filed 2026-03-19 | |
| 2023-09-30 | $730.00K 10-Q · filed 2024-11-12 | $1.51M derived: sum of 2 quarters · filed 2024-11-12 | $2.39M 10-Q · filed 2024-11-12 | $3.52M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | $785.00K 10-Q · filed 2024-08-08 | $1.66M 10-Q · filed 2024-08-08 | $2.79M derived: sum of 3 quarters · filed 2024-08-08 | $3.74M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $872.00K 10-Q · filed 2024-05-09 | $2.00M derived: sum of 2 quarters · filed 2024-05-09 | $2.95M derived: sum of 3 quarters · filed 2024-05-09 | $4.01M derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | $1.13M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $2.08M derived: sum of 2 quarters · filed 2024-03-14 | $3.13M derived: sum of 3 quarters · filed 2024-03-14 | $4.22M 10-K · filed 2024-03-14 | $4.22M 10-K · filed 2025-03-18 |
| 2022-09-30 | $949.00K 10-Q · filed 2023-11-09 | $2.00M derived: sum of 2 quarters · filed 2023-11-09 | $3.09M 10-Q · filed 2023-11-09 | $3.95M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-06-30 | $1.06M 10-Q · filed 2023-08-10 | $2.14M 10-Q · filed 2023-08-10 | $3.00M derived: sum of 3 quarters · filed 2024-03-14 | $4.01M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-03-31 | $1.08M 10-Q · filed 2023-05-11 | $1.95M derived: sum of 2 quarters · filed 2024-03-14 | $2.96M derived: sum of 3 quarters · filed 2024-03-14 | $3.79M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-12-31 | $863.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $1.87M derived: sum of 2 quarters · filed 2024-03-14 | $2.71M derived: sum of 3 quarters · filed 2024-03-14 | $3.38M 10-K · filed 2024-03-14 | |
| 2021-09-30 | $1.01M 10-Q · filed 2022-11-10 | $1.84M derived: sum of 2 quarters · filed 2022-11-10 | $2.52M 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $836.00K 10-Q · filed 2022-08-11 | $1.51M 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | $673.00K 10-Q · filed 2022-05-12 | ||||
| 2020-12-31 | $2.58M 10-K · filed 2023-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |